Posted by Michael Wonder on 15 Jul 2026
FDA approves Leqembi Iqlik (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
13 July 2026 - BioArctic's partner Eisai today announced that the US FDA has approved a supplemental biologics license application for a once weekly lecanemab irmb subcutaneous injection (Leqembi Iqlik) as a starting dose for the treatment of early Alzheimer's disease.
The US launch is planned for late August 2026.
